However, with FAK and PYK2 reported to have both redundant and specific functions across multiple cell types [12], it is not yet known whether FAK-selective or dual FAK/PYK2 inhibition will be most effective in driving anti-tumour immunity in the clinic. Here, PTK2 is linked to neoplasm.